Leadership reshuffle reflects company’s long-term vision for innovation, integration, and global impact across medtech and data-driven healthcare

As the cell and blood technologies space continues to evolve at pace, Terumo Blood and Cell Technologies (Terumo BCT) has brought in industry veteran Patrick Daly as its new Chief Business Officer, a move designed to unify the company’s offerings and boost enterprise-wide growth.

Daly brings more than three decades of healthcare and commercial experience, having worked across strategic marketing, business development, and executive leadership roles at Johnson & Johnson, Cohera Medical, and most recently, IQVIA. There, he built the MedTech Global Data franchise, focusing on turning data into monetized solutions for life sciences customers around the world.

Announcing the appointment, Terumo BCT President and CEO Antoinette Gawin said Daly’s ability to integrate commercial and data-driven strategies will help unlock the company’s next growth phase.

“Patrick’s experience acquiring capital and building strategic partnerships complements his experience monetizing data and solutions,” Gawin said. “This uniquely positions him to integrate our offerings and drive innovation across our business models and go-to-market strategies. His diverse experience will help accelerate our ambitions for double-digit growth.”

Daly’s remit will likely span both established blood technologies and the company’s rapidly expanding cell therapy and software platforms, as the medtech firm continues to blend product, service, and digital capabilities into a cohesive global strategy.

“It is a great moment to join Terumo BCT as it continues executing its long-term vision for growth and to meet patients’ unmet needs globally,” Daly said. “I am focused on ensuring our full portfolio, connected with data, software and services, will play a growing role in helping our customers solve healthcare’s toughest challenges.”

The move signals a broader shift among medtech firms toward integrated business models that pair traditional medical device expertise with digital transformation and data monetization. Terumo BCT already serves customers in over 150 countries, including blood centers, hospitals, apheresis clinics, cell therapy organizations, and research institutions. The company holds more than 750 granted patents, with a further 150 pending—highlighting its ongoing commitment to innovation.

As the global demand for personalised medicine, cell therapies, and smarter blood management rises, Daly’s appointment underscores Terumo BCT’s readiness to scale its impact—and play a pivotal role in shaping the future of therapeutic development and patient care.